Ligand Pharmaceuticals Incorporated
LGND
$159.44
$0.650.41%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 40.54% | 53.40% | 27.28% | -0.76% | -25.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 40.54% | 53.40% | 27.28% | -0.76% | -25.82% |
| Cost of Revenue | 139.92% | 134.41% | -7.28% | -44.89% | -54.51% |
| Gross Profit | 7.55% | 21.37% | 39.86% | 26.56% | -6.20% |
| SG&A Expenses | 50.38% | 63.57% | 48.99% | 1.64% | -13.16% |
| Depreciation & Amortization | 0.04% | -0.81% | -2.07% | -2.41% | -3.41% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.86% | 65.50% | 18.62% | -16.24% | -28.48% |
| Operating Income | -279.21% | -1,090.97% | 134.41% | 359.77% | 78.72% |
| Income Before Tax | -259.40% | -232.52% | -96.04% | -16.81% | -44.32% |
| Income Tax Expenses | -179.43% | -212.92% | -33.44% | -72.64% | -79.95% |
| Earnings from Continuing Operations | -280.02% | -237.65% | -107.49% | 114.46% | 2.75% |
| Earnings from Discontinued Operations | -- | -- | -- | 100.00% | 100.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -280.02% | -237.65% | -107.73% | 174.52% | 55.18% |
| EBIT | -279.21% | -1,090.97% | 134.41% | 359.77% | 78.72% |
| EBITDA | -55.10% | -47.78% | 25.72% | 68.15% | -7.08% |
| EPS Basic | -264.26% | -230.86% | -101.63% | 172.62% | 53.72% |
| Normalized Basic EPS | -295.14% | -932.34% | -12.12% | 147.99% | 20.67% |
| EPS Diluted | -273.26% | -233.88% | -105.55% | 198.62% | 59.04% |
| Normalized Diluted EPS | -299.40% | -949.84% | -7.81% | 141.46% | 35.80% |
| Average Basic Shares Outstanding | 7.51% | 6.81% | 5.74% | 4.43% | 3.65% |
| Average Diluted Shares Outstanding | 7.45% | 5.22% | 3.93% | 3.25% | 2.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |